SEMI-DISPOSABLE INSULIN PATCH PUMP: THE BEST SOLUTION FOR DIABETES PATIENTS

Información del proyecto

DiAMS

Identificador del acuerdo de subvención: 867975

DOI

10.3030/867975

Proyecto cerrado

Fecha de la firma de la CE 6 Mayo 2019

Fecha de inicio 1 Junio 2019

Fecha de finalización 30 Noviembre 2019

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

AMF MEDICAL SA
Switzerland

Periodic Reporting for period 1 - DiAMS (SEMI-DISPOSABLE INSULIN PATCH PUMP: THE BEST SOLUTION FOR DIABETES PATIENTS )

Período documentado: 2019-06-01 hasta 2019-11-30

Resumen del contexto y de los objetivos generales del proyecto

More than 420 M people live with diabetes globally (~60 M in Europe) and they will be 642 M by 2040. Diabetes is a significant economic burden, set to reach ~$2.5 trillion by 2030, and a big portion of costs corresponds to a poor management of the disease (specially inadequate insulin delivery). Hence, new cost-effective, less invasive and more accurate solutions for insulin treatment are a vital need. AMF is an innovative Swiss company and we have created the unprecedent insulin management system DiAMS (hardware+software), based on a semi-disposable patch pump, to make automated insulin therapy easier and more effective. It uniquely integrates a proprietary microfluidics technology, glucose monitoring, insulin delivery and control from a smartphone. We have obtained and preliminary tested first prototypes and now our main objectives are progress in optimization, clinical validation and certification and set the bases for manufacturing and future commercialization and scaling-up of our company in Europe and globally.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

The development of the feasibility study gave us the opportunity to perform a deep analysis of our project regarding technical, regulatory and commercial issues, and identify main requirements and needs to complete the development of our ground-breaking devices and to deploy them into the market. We could establish a regulatory roadmap and a robust commercial strategy, as well as identify key stakeholders, target users and potential markets. We defined financial needs and growing potential for our company once we reach the market. We have decided to continue with our promising project and initially built-up a workplan for next years, considering all pending activities.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

DiAMS will disrupt insulin therapy. It is invisible to others and worry-free for the user. Its interface is user’s personal smart devices and our patch pump will be the lightest, the thinnest and the most comfortable to wear on the market. Insulin management will be simplified, our pump eliminates bubbles and it is the first one using prefilled cartridges. We target type 1 and type 2 diabetes patients, but we expect children/young people with type 1 diabetes to benefit the most in treatment and life’s quality. We offer high accuracy and effective self-management to control of glycemia at minimal pain, low complexity and highest discretion. Patients will avoid the need of specialized medical assistance and implement long-term treatment without altering their routines.

Company logo